Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPARK: Low Dose Radiotherapy + Sintilimab + Chemo for NSCLC
NCT06714708Phase 2Recruiting
- Sponsor
- Anhui Provincial Tumor Hospital
- Start
- Nov 2024
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial (2 arms), sponsored by Anhui Provincial Tumor Hospital. Primary endpoint: Pathologic Complete Response rate. Started Nov 2024; status: recruiting.
Beyond the preview
Go deeper on NCT06714708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06714708.